Target type: biologicalprocess
Any process that increases the rate, frequency, or extent of inclusion body assembly. Inclusion body assembly is the aggregation, arrangement and bonding together of a set of components to form an inclusion body. [GOC:tb]
Positive regulation of inclusion body assembly is a complex cellular process that involves the formation of protein aggregates within the cytoplasm of cells. These aggregates, known as inclusion bodies (IBs), are often composed of misfolded or aggregated proteins that are unable to fold properly. While generally considered detrimental, inclusion bodies can also play a role in certain cellular processes and are of particular interest in biotechnology for their potential in protein production.
The formation of inclusion bodies is a highly regulated process influenced by various factors, including protein sequence, expression level, and cellular environment. Key players in the positive regulation of inclusion body assembly include:
* **Chaperones:** These proteins assist in protein folding and prevent aggregation. However, under stress conditions or when proteins are prone to misfolding, chaperones can become overwhelmed and promote IB formation.
* **Ubiquitin-Proteasome System (UPS):** The UPS is responsible for degrading misfolded proteins. While it typically prevents aggregation, a high load of misfolded proteins can overwhelm the UPS, leading to the formation of IBs.
* **Oxidative Stress:** Increased levels of reactive oxygen species (ROS) can induce protein misfolding and aggregation, thereby promoting IB formation.
* **Cell Stress:** Environmental stressors like heat shock or nutrient deprivation can trigger the unfolded protein response (UPR), a cellular stress response that can lead to increased protein aggregation and IB formation.
While inclusion bodies are often associated with disease, their formation can also be beneficial. In biotechnology, the ability to control and optimize inclusion body formation is crucial for recombinant protein production.
In summary, positive regulation of inclusion body assembly involves a complex interplay between cellular mechanisms that aim to prevent protein aggregation and factors that promote it. Understanding the intricacies of this process is crucial for mitigating its detrimental effects in disease contexts and harnessing its potential for biotechnological applications.'
"
Protein | Definition | Taxonomy |
---|---|---|
Heat shock factor protein 1 | A heat shock factor protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q00613] | Homo sapiens (human) |
26S proteasome regulatory subunit 10B | A 26S proteasome regulatory subunit 10B that is encoded in the genome of human. [PRO:DNx, UniProtKB:P62333] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
zm 336372 | N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source | benzamides | |
celastrol | monocarboxylic acid; pentacyclic triterpenoid | anti-inflammatory drug; antineoplastic agent; antioxidant; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Hsp90 inhibitor; metabolite | |
bortezomib | amino acid amide; L-phenylalanine derivative; pyrazines | antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor | |
quercetin | 7-hydroxyflavonol; pentahydroxyflavone | antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger | |
carfilzomib | epoxide; morpholines; tetrapeptide | antineoplastic agent; proteasome inhibitor | |
chir-265 | aromatic ether | ||
az-628 | AZ-628: a multikinase inhibitor; structure in first source | benzamides | |
GDC-0879 | indanes; ketoxime; primary alcohol; pyrazoles; pyridines | antineoplastic agent; B-Raf inhibitor | |
belactosin a | belactosin A: isolated from Streptomyces; structure in first source | ||
plx4032 | aromatic ketone; difluorobenzene; monochlorobenzenes; pyrrolopyridine; sulfonamide | antineoplastic agent; B-Raf inhibitor | |
dabrafenib | 1,3-thiazoles; aminopyrimidine; organofluorine compound; sulfonamide | anticoronaviral agent; antineoplastic agent; B-Raf inhibitor | |
tak-632 | TAK-632 : A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by (cyclopropanecarbonyl)amino, 4-fluoro-3-{2-[3-(trifluoromethyl)phenyl]acetamido}phenoxy, and cyano groups at positions 2, 6 and 7, respectively. It is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAF(V600E), BRAF(WT), respectively. | (trifluoromethyl)benzenes; aromatic ether; benzothiazoles; cyclopropylcarboxamide; monofluorobenzenes; nitrile; secondary carboxamide | antineoplastic agent; apoptosis inducer; B-Raf inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; necroptosis inhibitor |
dinaciclib | pyrazolopyrimidine | ||
n2-(1h-indazole-5-yl)-n6-methyl-3-nitropyridine-2,6-diamine | KRIBB11 : A member of the class of indazoles that is 1H-indazole substituted by a [6-(methylamino)-3-nitropyridin-2-yl]amino group at position 5. It is an inhibitor of heat shock factor 1 (IC50 = 1.2muM) and suppresses tumour growth in mouse xenograft models. N2-(1H-indazole-5-yl)-N6-methyl-3-nitropyridine-2,6-diamine: a heat shock factor 1 antagonist; structure in first source |